Eleven Biotherapeutics Inc., of Cambridge, Mass., filed with the SEC to raise $12.5 million in a public offering. The number of shares and share price have not yet been disclosed. Proceeds are expected to fund clinical development of Vicinium, a locally administered targeted protein therapeutic, and for general corporate purposes. H.C. Wainwright & Co. is acting as the sole book-running manager. Shares of Eleven (NASDAQ:EBIO) closed Thursday at $1.51, down 8 cents.